Despite today’s buyout offer, Celera has to rank as one of the biggest biotech busts of all time. Since CRA has about $325M of net current assets, the buyout price of $657M equates to an enterprise value of only $330M or so. That’s not a lot for a company that has lost $1B since its inception.